Similar articles

• [Liberation of hydrocortisone acetate from different commercial formulations].

  Neubert RH, Pötzsch A. Neubert RH, et al. Pharmazie. 2004 Jun;59(6):472-4. Pharmazie. 2004. PMID: 15248463 German.
• 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.

  Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R; European Tacrolimus Ointment Group. Reitamo S, et al. Br J Dermatol. 2004 Mar;150(3):554-62. doi: 10.1046/j.1365-2133.2004.05782.x. Br J Dermatol. 2004. PMID: 15030341 Clinical Trial.
• Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx.

  Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, Rehm M, Conzen P, Welsch U, Becker BF. Chappell D, et al. Anesthesiology. 2007 Nov;107(5):776-84. doi: 10.1097/01.anes.0000286984.39328.96. Anesthesiology. 2007. PMID: 18073553
• Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.

  Borelli C, Gassmueller J, Fluhr JW, Nietsch KH, Schinzel S, Korting HC. Borelli C, et al. Skin Pharmacol Physiol. 2008;21(3):181-7. doi: 10.1159/000131082. Epub 2008 Jun 3. Skin Pharmacol Physiol. 2008. PMID: 18523415 Clinical Trial.
• A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.

  Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C; European Tacrolimus Ointment Study Group. Reitamo S, et al. Br J Dermatol. 2005 Jun;152(6):1282-9. doi: 10.1111/j.1365-2133.2005.06592.x. Br J Dermatol. 2005. PMID: 15948994 Clinical Trial.